NBE-Therapeutics has obtained a granted patent for the company's core SMAC-Technology in the United States
Today, NBE-Therapeutics annouces that the United States Patent and Trademark Office (USPTO) has recently granted US Patent 9,872,923 B2. The patent entitled "Method of producing an immunoligand/payload conjugate" discloses the company's core SMAC-Technology platform for generating site-specifically conjugated antibody drug conjugates (ADCs) by means of sortase-enzyme catalysis. This granted US patent marks an important milestone in the development of the company and it is already the second core technology of NBE-Therapeutics with granted patents in major jurisdictions. In addition, the company has previously received granted patents for its antibody discovery technology platform, called Transpo-mAb Display, which NBE-Therapeutics is utilizing to develop humanized and/or fully human antibodies as a basis for NBE-Therapeutics' ADC product pipeline. The company currently has about a dozen patent families covering the company's ADC technologies and product developments, of which seven families are already published. NBE-Therapeutics pursues a professional IP strategy in order to built the foundation for future commercialization of the company's innovations and developments.
TargImmune successfully closed its 2021 financing round and ...
Monte Rosa Therapeutics raises USD222 million in successful ...
Alentis Therapeutics Raises USD 67 Million in Series B Fina...
Virtual Auditorium Talk: ‘How to attract and retain best t...